Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Historic Current Deferred Revenue for Cogent Biosciences (COGT) over the last 4 years, with Q2 2020 value amounting to $312000.0.

  • Cogent Biosciences' Current Deferred Revenue fell 9794.74% to $312000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $312000.0, marking a year-over-year decrease of 9794.74%. This contributed to the annual value of $1.3 million for FY2019, which is 9267.37% down from last year.
  • According to the latest figures from Q2 2020, Cogent Biosciences' Current Deferred Revenue is $312000.0, which was down 9794.74% from $841000.0 recorded in Q1 2020.
  • Over the past 5 years, Cogent Biosciences' Current Deferred Revenue peaked at $20.4 million during Q2 2018, and registered a low of $312000.0 during Q2 2020.
  • Over the past 4 years, Cogent Biosciences' median Current Deferred Revenue value was $15.2 million (recorded in 2019), while the average stood at $12.0 million.
  • As far as peak fluctuations go, Cogent Biosciences' Current Deferred Revenue surged by 16047.02% in 2018, and later plummeted by 9794.74% in 2020.
  • Quarter analysis of 4 years shows Cogent Biosciences' Current Deferred Revenue stood at $6.9 million in 2017, then skyrocketed by 160.47% to $17.9 million in 2018, then tumbled by 92.67% to $1.3 million in 2019, then crashed by 76.27% to $312000.0 in 2020.
  • Its Current Deferred Revenue stands at $312000.0 for Q2 2020, versus $841000.0 for Q1 2020 and $1.3 million for Q4 2019.